<DOC>
	<DOC>NCT01776814</DOC>
	<brief_summary>Chronic hepatitis B virus infection is an important cause of morbidity and mortality. Tenofovir disoproxil fumarate and entecavir were licensed for the treatment of hepatitis B virus infection. In this study, the investigators will try to make comparison between Entecavir and Tenofovir and investigate the efficacy.</brief_summary>
	<brief_title>Comparison of the Efficacy of Entecavir and Tenofovir Monotherapy for the Treatment of Nucleos(t)Ide-na√Øve Patients With Chronic Hepatitis B in Korea</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>18 &lt; Age &lt; 70 HBV DNA &gt; 100,000 copies/mL and increased ALT over 2 times compared with normal range if HBsAg (+), HBeAg (+) HBV DNA &gt; 10,000 copies/mL and increased ALT compared with normal range if HBsAg (+), HBeAg () With HCV or other liver disease With kidney disease decompensated liver cirrhosis with hepatocellular carcinoma refuse this clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Entecair</keyword>
	<keyword>Tenofovir</keyword>
</DOC>